In the world of New York No-Fault and DME claim reviews, our team has learned to expect the occasional surprise.
Questionable invoices? Of course.
Creative coding? Regularly.
Medical necessity that seems to have wandered far outside standard treatment guidelines? More often than one would hope.
But few billing trends are quite as fascinating as the repeated appearance of external bone growth stimulators prescribed for what are, on paper, straightforward soft tissue injuries.
Yes… bone growth stimulators.
For sprains.
Let’s Start With What These Devices Are Actually Designed For
Among the more expensive DME items commonly billed in PIP and No-Fault cases are:
- E0747 – External non-spinal osteogenesis stimulator
- E0748 – External spinal osteogenesis stimulator
The terminology itself tells the story.
“Osteo” refers to bone. “Genesis” refers to formation or growth. In other words:
These devices are intended to stimulate bone healing.
According to the Centers for Medicare and Medicaid Services (CMS) National Coverage Determination, this device can be prescribed as indicated ONLY for serious medical circumstances such as:
- Failed spinal fusion
- Nonunion fractures
- Delayed bone healing lasting six months or longer
- Congenital pseudarthrosis
- Severe orthopedic complications
According to the U.S. Department of Health and Human Services Office of Inspector General (OIG) report: “Medicare only pays for a bone growth stimulator, which costs approximately $4,000, if the medical supplier provides records demonstrating that fracture healing has ceased for three or more months.”
These are not casual treatment tools.
They are specialized, high-cost devices often ranging between $3,000 and $5,000.
In legitimate cases, they serve an important purpose.
So Naturally… They’re Being Billed for Muscle Injuries?
This is where things become considerably more interesting.
Rather than seeing these devices consistently tied to severe fractures, failed surgical outcomes, or long-term bone healing disorders, our team frequently encounters them prescribed to motor vehicle accident patients diagnosed primarily with:
- Cervical sprains
- Lumbar strains
- Soft tissue (muscle) injuries
- Generalized back pain
- Minor musculoskeletal trauma
Which raises an obvious question:
Why exactly does a strained back muscle require advanced bone-growth technology?
Unless whiplash has suddenly evolved into a bone-regeneration crisis, the clinical rationale often appears difficult to support.
The Documentation: Frequently as Unclear as the Medical Necessity
Adding to the concern, the supporting prescriptions submitted with these claims are often… less than inspiring. Our reviews commonly encounter documentation that includes:
- Blurry scanned pages
- Missing patient identifiers
- Absent treatment dates
- Illegible handwriting
- Missing physician signatures
- Minimal clinical justification
- Generic device recommendations without condition-specific rationale
At times, the prescriptions appear so incomplete that one wonders whether the copier itself had concerns.
When a $5,000 device is being recommended, one would expect robust documentation clearly explaining:
- Why conventional treatment failed
- Why bone stimulation is medically indicated
- What objective findings support usage
- How the diagnosis aligns with device purpose
Instead, what often arrives looks more like reimbursement support paperwork assembled as an afterthought.
Traditional Treatment vs. Luxury Billing
For many soft tissue injuries, evidence-based treatment guidelines more commonly support conservative therapies such as:
- Physical therapy
- NSAIDs
- Chiropractic care
- Trigger point injections
- Home exercise
- TENS units
A TENS unit, for example, may cost roughly $50.
An osteogenesis stimulator?
Potentially $5,000.
So one cannot help but ask:
Is this truly about clinical innovation… or reimbursement optimization?
Because from a billing perspective, the difference is substantial.
The Financial Anatomy of “Creative Medical Necessity”
When lower-cost, guideline-supported treatments are bypassed in favor of highly specialized orthopedic devices designed primarily for severe bone pathology, insurers and SIU teams have every reason to scrutinize:
- Medical necessity
- Prescribing patterns
- Provider relationships
- Documentation quality
- Potential overutilization
- Fraud indicators
While not every case is inherently improper, recurring patterns of expensive device utilization in clinically inconsistent scenarios deserve attention.
Final Thoughts from our DME Review Desk
Bone growth stimulators serve an important role in medicine.
For failed fusions.
For true nonunions.
For serious skeletal healing disorders.
But when these same devices begin appearing routinely in claims involving uncomplicated sprains and strains, questions naturally follow.
Because, while soft tissue injuries can absolutely be painful…
They generally do not require stimulating bone that was never broken.
At AJHC, our team routinely evaluates DME submissions for medical necessity, documentation integrity, and reimbursement compliance.
And sometimes, the biggest red flag is not the diagnosis—
It’s the extraordinary device somehow attached to it.